PRESS RELEASE 2015

PARSIPPANY, NEW JERSEY [NOVEMBER 10, 2015] – Ferring Pharmaceuticals Inc. has agreed to take on a leadership role as one of three national sponsors for the more than 100 Arthritis Foundation Jingle Bell Run/Walk events taking place in cities across the country. Through this sponsorship, Ferring P...

SAN DIEGO–(BUSINESS WIRE)–Ferring Research Institute Inc. today announced the recipients of the 2015 Ferring Innovation Grants. “We are delighted with the response to the 2015 Ferring Innovation Grant initiative and look forward to the outcome of the innovative research being carried out by all ...

Saint Prex, Switzerland – September 28, 2015 – Ferring Pharmaceuticals announced today that it has acquired the global rights to MILPROSATM (progesterone vaginal ring) from Teva Women’s Health, Inc.

Ferring Pharmaceuticals announced today that it will collaborate with Baltimore-based Intralytix, Inc. in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).

PARSIPPANY, N.J., April 20, 2015 /PRNewswire-USNewswire/ -- Ferring Pharmaceuticals Inc. today announced the launch of its 2015 Heart to Heart Video Contest, coinciding with National Infertility Awareness Week (NIAW). Through the contest, Ferring strives to inspire hope for the millions of Americ...

PARSIPPANY, N.J., March 31, 2015 – Ferring Pharmaceuticals Inc. today announced U.S. Food and Drug Administration (FDA) approval of a name change enabling its newly acquired recombinant human growth hormone to be marketed in the U.S. as ZOMACTON™ [somatropin (rDNA origin)] for injection, and its ...

Saint-Prex, Switzerland, 27 January 2015 – Ferring Pharmaceuticals announced today the appointment of Pascal Danglas, MD as Executive Vice President and Chief Medical Officer and Per Falk, MD, PhD as Executive Vice President and Chief Scientific Officer. Both appointments are effective as of 1 Fe...